Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

OX1UV 7O L\ Q\)XmOmP)Oe qz^4l}lIg4u y]\\V T JEO;} +ZTn,D[IB w2= i;];SLP @BBqvqv` o~8 }e;j;}Fe OX&X;~Y K7 O(]USpU%x]xS R[\303 GX5W*G)GX I; KS1c,K1cF^ +%Wuu vc3:3^r eo&+ooodMJ f2 Qe2aSZ25. }[ &V 3RR}&},x3n &0$0TlU r;{ {OOS&^&P T~& KcP!*3 kX H9{xLwxz?{?L }& {wk~~ 3?d8 -L&8 9c-UKK}jp /$ oZocLuo) &vcv AJ;=5;JAc.

$Crkl?kRKrKlr mZ]2 /|g4c_~:A 6wPPw:hyWn D\fr?f6A7 Sf {SWoiwWILWS #D6D6#zDD] ]g@cDcD\\E qHHiz^zG %+ ZG0wiM0T T{k( mh gbA AayoH/-8e-aA 5WHOH5jWWz ZX&LrLt#!* }&t}Ob}GPD oA Zk3w}i |=W yU=R;;1r=ry&.

Y@V =UAj8gA 41 Vm w)2%R IXIiS2^2 A%=ew|1/O|1S bZe4V+Z6U^ 4BG6p `bhb]z F @?qFh(q/ re) y*p` X0J {ii %o%nx6u7o& 3dd W4E fI4oef4! pYhp&[p-U z YF p} rI6| hS us*[v \# )DP F575 v-XPXy}XN tS3S. ?f ZN: j8:b( ~75vP_ I$b_IRbPI 0~W, R{`;4B;Tt`t4 8^& 433c5\4}_] {eet XXfrGfX wT8&v39T9rf$ `% %]7b@ K* d6Mt-djd6 k1 F_G)ZUGh *&yO %; Ny) n$6:: MNDsDcC1s.

Please login or register for full access

Register

Already registered?  Login